Eli Lilly's Gene Editing Therapy Shows Promise in Lowering Cholesterol
Eli Lilly has announced encouraging results from a recent clinical trial of its gene-editing therapy, indicating a significant reduction in cholesterol levels among participants.
In a recent clinical trial, Eli Lilly reported a notable reduction in cholesterol levels attributed to its gene-editing therapy. The findings suggest a potential advancement in cholesterol management strategies.
Specifically, the high dose of the therapy resulted in a 62% decrease in cholesterol among early trial participants. These results are still preliminary and stem from a Phase 1 clinical trial.
The implications of this therapy could be significant for those struggling with cholesterol-related health issues, although further research will be necessary to confirm these findings and assess long-term effects.
Updates
Update at 13:28 UTC on 2026-05-26
STAT reported Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial.
Sources: STAT